With a successful music career already in the bag, 24-year-old Fredrik Guzmán Lindemark is now making his mark as a start-up entrepreneur and investor.
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.